Ontology highlight
ABSTRACT:
SUBMITTER: Janssen J
PROVIDER: S-EPMC7914531 | biostudies-literature | 2021 Feb
REPOSITORIES: biostudies-literature
Janssen Jeroen J Löwenberg Bob B Manz Markus M Bargetzi Mario M Biemond Bart B Borne Peter von dem PVD Breems Dimitri D Brouwer Rolf R Chalandon Yves Y Deeren Dries D Efthymiou Anna A Gjertsen Bjørn-Tore BT Graux Carlos C Gregor Michael M Heim Dominik D Hess Urs U Hoogendoorn Mels M Jaspers Aurelie A Jie Asiong A Jongen-Lavrencic Mojca M Klein Saskia S Klift Marjolein van der MV Kuball Jürgen J Lammeren-Venema Danielle van DV Legdeur Marie-Cecile MC Loosdrecht Arjan van de AV Maertens Johan J Kooy Marinus van Marwijk MVM Moors Ine I Nijziel Marten M Obbergh Florence van FV Oosterveld Margriet M Pabst Thomas T Poel Marjolein van der MV Sinnige Harm H Spertini Olivier O Terpstra Wim W Tick Lidwine L Velden Walter van der WV Vekemans Marie-Christiane MC Vellenga Edo E Weerdt Okke de O Westerweel Peter P Stüssi Georg G Norden Yvette van YV Ossenkoppele Gert G
Cancers 20210207 4
Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in phase of the study in 22 patients, 231 eligible patients with AML above 65 years of age (median 70, range 66-81) were randomly assigned in this open label randomized Phase II study to receive standard chemotherapy (3+7) with or without tosedostat at th ...[more]